Embecta Corp.

Report azionario NasdaqGS:EMBC

Capitalizzazione di mercato: US$231.4m

Embecta Performance degli utili passati

Criteri Il passato verificati 4/6

Gli utili di Embecta sono diminuiti a un tasso medio annuo di -43.6%, mentre il settore Medical Equipment ha visto gli utili crescere a un tasso medio annuo di 10.4%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 1.9%.

Informazioni chiave

-43.62%

Tasso di crescita degli utili

-43.12%

Tasso di crescita dell'EPS

Medical Equipment Crescita del settore8.90%
Tasso di crescita dei ricavi-1.92%
Rendimento del capitale proprion/a
Margine netto10.73%
Ultimo aggiornamento sugli utili31 Mar 2026

Aggiornamenti sulle prestazioni recenti

Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively

Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively

Recent updates

EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets

Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.

EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside

Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.

Embecta: An Interesting Deal At An Interesting Time

Mar 19

EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook

Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).

Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively

Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple

Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.

EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple

Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.

Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings

Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings

EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures

Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).

EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026

Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.

US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results

Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results

Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?

Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?

Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price

Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely

Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely

GLP-1 Partnerships Will Expand Global Healthcare Reach

The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.

Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)

Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15

What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?

May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?

Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price

Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price

Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour

Feb 28

New Initiatives Expected To Make Embecta More Profitable

Dec 04

Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15

Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15

At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?

Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?

It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)

Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
User avatar

Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies

Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.

Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Aug 16
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15

Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next

Aug 14
Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next

When Should You Buy Embecta Corp. (NASDAQ:EMBC)?

Jul 13
When Should You Buy Embecta Corp. (NASDAQ:EMBC)?

Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

Feb 21
Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15

Ripartizione dei ricavi e delle spese

Come Embecta guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NasdaqGS:EMBC Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
31 Mar 261,04311232518
31 Dec 251,08014033017
30 Sep 251,0809533426
30 Jun 251,1038434441
31 Mar 251,0805334558
31 Dec 241,1085835772
30 Sep 241,1237836579
30 Jun 241,1197036483
31 Mar 241,1337036685
31 Dec 231,1225535989
30 Sep 231,1217034185
30 Jun 231,1144732880
31 Mar 231,1199432471
31 Dec 221,11616030567
30 Sep 221,13022429567
30 Jun 221,15633828469
31 Mar 221,16038026070
31 Dec 211,16940824966
30 Sep 211,16541524063
30 Sep 201,08642821561
30 Sep 191,10943222262

Guadagni di qualità: EMBC ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di EMBC (10.7%) EMBC sono più alti rispetto allo scorso anno (4.9%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di EMBC sono diminuiti del 43.6% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di EMBC nell'ultimo anno ( 111.9% ) supera la media quinquennale ( -43.6% all'anno).

Guadagni vs Settore: La crescita degli utili EMBC nell'ultimo anno ( 111.9% ) ha superato la percentuale del settore Medical Equipment 13.2%.

Rendimento del capitale proprio

ROE elevato: Le passività di EMBC superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/06 03:07
Prezzo dell'azione a fine giornata2026/05/06 00:00
Utili2026/03/31
Utili annuali2025/09/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Embecta Corp. è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Travis SteedBofA Global Research
Travis SteedBofA Global Research
Michael GormanBTIG